Division of General Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA
Division of General Medicine & Clinical Epidemiology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
BMJ Open. 2021 Jul 9;11(7):e045160. doi: 10.1136/bmjopen-2020-045160.
To examine if a decision aid improves knowledge of lung cancer screening benefits and harms and which benefits and harms are most valued.
Pre-post study.
Online.
219 current or former (quit within the previous 15 years) smokers ages 55-80 with at least 30 pack-years of smoking.
Lung cancer screening video decision aid.
Screening knowledge tested by 10 pre-post questions and value of benefits and harms (reducing chance of death from lung cancer, risk of being diagnosed, false positives, biopsies, complications of biopsies and out-of-pocket costs) assessed through rating (1-5 scale) and ranking (top three ranked).
Mean age was 64.7±6.1, 42.5% were male, 75.4% white, 48.4% married, 28.9% with less than a college degree and 67.6% with income <US$50 000. Knowledge improved postdecision aid (pre 2.8±1.8 vs post 5.8±2.3, diff +3.0, 95% CI 2.7 to 3.3; p<0.001). For values, reducing the chance of death from lung cancer was rated and ranked highest overall (rating 4.3±1.0; 59.4% ranked first). Among harms, avoiding complications (3.7±1.3) and out-of-pocket costs (3.7±1.2) rated highest. Thirty-four per cent ranked one of four harms highest: avoiding costs 13.2%, false positives 7.3%, biopsies 7.3%, complications 5.9%. Screening intent was balanced (1-4 scale; 1-not likely 21.0%, 4-very likely 26.9%). Those 'not likely' to screen had greater improvement in pre-post knowledge scores and more frequently ranked a harm first than those 'very likely' to screen (pre-post diff:+3.5 vs +2.6, diff +0.9; 95% CI 0.1 to 1.8; p=0.023; one of four harms ranked first: 28.4% vs 11.3%, p<0.001).
Our decision aid increased lung cancer screening knowledge among a diverse sample of screen-eligible respondents. Although a majority valued 'reducing the chance of death from lung cancer' highest, a substantial proportion identified harms as most important. Knowledge improvement and ranking harms highest were associated with lower intention to screen.
研究决策辅助工具是否能提高对肺癌筛查益处和危害的认识,以及哪些益处和危害最受重视。
前后对照研究。
在线。
219 名当前或曾经(在过去 15 年内戒烟)吸烟者,年龄在 55-80 岁之间,吸烟至少 30 包年。
肺癌筛查视频决策辅助工具。
通过 10 个前后问题测试筛查知识,通过评分(1-5 分制)和排名(排名前三)评估益处和危害(降低死于肺癌的几率、被诊断出的风险、假阳性、活检、活检并发症和自付费用)的价值。
平均年龄为 64.7±6.1 岁,42.5%为男性,75.4%为白人,48.4%已婚,28.9%未完成大学学业,67.6%收入<50000 美元。决策辅助工具使用后知识提高(使用前 2.8±1.8 分,使用后 5.8±2.3 分,差异为+3.0,95%置信区间为 2.7 至 3.3;p<0.001)。在价值方面,降低死于肺癌的几率总体上被评为和排名最高(评分 4.3±1.0;59.4%排名第一)。在危害方面,避免并发症(3.7±1.3)和自付费用(3.7±1.2)评分最高。34%的人将四种危害中的一种评为最高:避免费用 13.2%,假阳性 7.3%,活检 7.3%,并发症 5.9%。筛查意愿平衡(1-4 分制;1-不太可能 21.0%,4-非常可能 26.9%)。那些“不太可能”进行筛查的人,他们在前后知识评分上的提高更大,并且比那些“非常可能”进行筛查的人更频繁地将危害排在首位(前后知识评分差异:+3.5 分 vs +2.6 分,差异+0.9;95%置信区间 0.1 至 1.8;p=0.023;四种危害之一被评为首位:28.4% vs 11.3%,p<0.001)。
我们的决策辅助工具提高了筛查合格人群对肺癌筛查的认识。尽管大多数人认为“降低死于肺癌的几率”最重要,但仍有相当一部分人认为危害最重要。知识的提高和将危害排在首位与较低的筛查意愿有关。